All News
Filter News
Found 699 articles
-
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020
11/30/2020
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will host a conference call to provide a research and development (R&D) and Corporate update at 8:30 a.m. EST on December 9, 2020 . The call will include the Protagonist management team and Andrew Kuykendall , M.D., an investigator in the PTG-300
-
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference
11/25/2020
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30 to December 3, 2020 . The presentation will be available for registered
-
Imago BioSciences Raises $80 Million in Series C Financing
11/19/2020
– Proceeds to support advancing therapies for the treatment of myeloproliferative diseases through further clinical investigation – Financing round led by Farallon Capital Management, LLC
-
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference
11/11/2020
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference. Presentation details: Date: Tuesday, Nov. 17, 2020 Time: 5:35 p.m. GMT ( 12:35 p.m. EST
-
Interim Data From Imago BioSciences’ Phase 2b Study of Bomedemstat (IMG-7289) for Treatment of Myelofibrosis to Be Presented at 62nd American Society of Hematology Annual Meeting
11/5/2020
Imago BioSciences, Inc., (“Imago”) a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that interim data from its ongoing Phase 2b study evaluating bomedemstat (IMG-7289) for the treatment of myelofibrosis will be presented in an oral session during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually Dec. 5-8, 2020
-
Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
11/5/2020
Total product and royalty revenues of $621 million (+16% vs Q3 2019) for the quarter ended September 30, 2020; Jakafi ® (ruxolitinib) revenues of $488 million in Q3 2020 (+13% vs Q3 2019); Incyte tightens full year 2020 Jakafi revenue guidance to a range of $1.910 to $1.940 billion Strong momentum behind commercial launches of both Monjuvi ® (tafasitamab-cxix) and Pemazyre ® (pemigatinib) in the U.S.
-
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
11/4/2020
-- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 -- -- PTG-300 received European Medicine Agency (EMA) Orphan Drug Designation for the treatment of polycythemia vera -- -- Company is advancing additional oral IL-23 receptor antagonists into clinical development in collaboration with Janssen --
-
PharmaEssentia to Present Long-Term Data on Ropeginterferon Alfa-2b in Polycythemia Vera at Virtual ASH Annual Meeting
11/4/2020
Results from five-year PROUD-PV/CONTINUATION-PV studies in rare blood cancer featured as oral presentation
-
More than 40 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting
11/4/2020
Numerous abstracts, including 7 oral presentations, highlighting data for ruxolitinib, parsaclisib, tafasitamab and ponatinib to be exhibited
-
Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting
11/4/2020
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced the acceptance of one oral and four poster presentations at the American Society for Hematology (ASH) annual meeting, taking place in a virtual format December 5-8, 2020 . The abstract data includes results as of early August 2020 from the ongoing Phase 2 study of PTG
-
Protagonist Therapeutics Reports Granting of Inducement Award - Oct 30, 2020
10/30/2020
Protagonist Therapeutics, Inc. reported that on October 31, 2020, it issued an inducement award to Nora Boyer, the Company's recently hired Vice President, Medical Affairs, in accordance with the terms of Ms. Boyer's employment offer letter.
-
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
10/29/2020
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration agreement with Janssen Biotech, Inc., have been selected for advancement into clinical development. The two new candidates, PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186), are be
-
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
10/21/2020
PTG-300 was previously granted orphan drug designation by the U.S. Food and Drug Administration
-
Secarna Pharmaceuticals and Denali Therapeutics Enter Into Research and Option Agreement to Develop Novel Antisense Therapies in the Field of Neurodegenerative Diseases
10/13/2020
Secarna Pharmaceuticals GmbH today announced that the Company has signed a Research and Option Agreement with Denali Therapeutics Inc.
-
CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia
9/29/2020
- Company to Proceed with Rolling NDA Submission following Recent Pre-NDA Meeting with FDA - - Rolling NDA Expected to Commence in the Fourth Quarter of 2020 - - Completion of NDA Submission Expected in First Quarter 2021 - - Company to Host Conference Call on Wednesday, September 30 at 8:30 AM ET - [29-September-2020] SEATTLE , Sept. 29,
-
Health Canada Approves INREBIC® (fedratinib), First New Treatment in Nearly a Decade for Patients Living with Myelofibrosis
9/21/2020
INREBIC® provides new, once-daily oral option for patients affected by rare bone marrow cancer
-
Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020
9/17/2020
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Virtual Summit 2020.
-
Protagonist Therapeutics Reports Granting of Inducement Award - Sep 15, 2020
9/15/2020
Protagonist Therapeutics, Inc. reported that on September 15, 2020, it issued an inducement award to Matthew Gosling, the Company's recently hired Executive Vice President and General Counsel, in accordance with the terms of Mr. Gosling's employment offer letter.
-
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
9/10/2020
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference.
-
Imago BioSciences to Participate in Upcoming Investor Conferences
9/8/2020
Imago BioSciences, Inc . (“Imago”), a private clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that Hugh Young Rienhoff, Jr. M.D., chief executive officer, will present a corporate overview at two upcoming investor conferences. Citi’s 15 th Annual BioPharma Virtual Conference Date: Tuesday, September 8 th 2020 Time: 2:20 p.m.